

29. Mai 2019

---

## Vorankündigung: ASCO-Abstracts von Celgene

**Auf dem am Freitag beginnenden Treffen der American Society of Clinical Oncology (ASCO) in Chicago, Illinois, USA, stellt Celgene neue Forschungsergebnisse vor, darunter die TRANSCEND NHL 001-Studie zur CAR-T-Zell-Technologie mit Lisocabtagenen Maraleucel. Des weiteren werden Daten zur Myelofibrose (JAKARTA2-Studie mit Fedratinib) und zum multiplem Myelom mit Iberdomid sowie Ergebnisse der AFACT-Studie mit nab-Paclitaxel + Gemcitabin adjuvant beim resezierten Pankreaskarzinom vorgestellt.**

### **Abstract-Auswahl:**

#### *CAR-T*

Abstract [#7501](#): TRANSCEND CLL 004: Minimal residual disease (MRD) negative responses after lisocabtagene maraleucel (liso-cel; JCAR017), a CD19-directed CAR T cell product, in patients (Pts) with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL). (Oral presentation; Tuesday, June 4, 9:57 a.m. to 10:09 a.m., E451, lead author: Siddiqi)

Abstract #7515: Lisocabtagene maraleucel (liso-cel) treatment of patients (Pts) with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL) and secondary CNS lymphoma: Initial results from TRANSCEND NHL 001. (Poster Discussion; Monday, June 3, 11:30 a.m. to 1 p.m., E450, lead author: Abramson)

Abstract #7516: Safety and preliminary efficacy in patients (pts) with relapsed/refractory (R/R) mantle cell lymphoma (MCL) receiving lisocabtagene maraleucel (liso-cel) in TRANSCEND NHL 001. (Poster Discussion; Monday, June 3, 11:30 a.m. to 1 p.m., E450, lead author: Wang)

Abstract #6637: Burden of cytokine release syndrome (CRS) and neurologic events (NE) in patients (pts) with relapsed/refractory non-Hodgkin lymphoma (NHL) receiving lisocabtagene maraleucel (liso-cel; JCAR017) in TRANSCEND NHL 001. (Poster; Saturday, June 1, 1:15 p.m. to 4:15 p.m., Hall A, lead author: Abramson)

Abstract e19052: TRANSCEND NHL 001: Health-related quality of life (HRQL) and symptom (sx) impact in patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) receiving lisocabtagene maraleucel (liso-cel; JCAR017). (ePub only, lead author: Patrick)

#### *Lymphom*

Abstract #7513: MAGNIFY: Phase IIIb interim analysis of induction R2 followed by maintenance in relapsed/refractory indolent non-Hodgkin lymphoma (Poster Discussion; Monday, June 3, 11:30 a.m. to 1 p.m., E450, lead author: Andorsky)

Abstract [#7514](#): Efficacy and time to next treatment following lenalidomide/rituximab (R2) or rituximab/placebo in patients with R/R indolent NHL (AUGMENT). (Poster Discussion; Monday, June 3, 11:30 a.m. to 1 p.m., E450, lead author: Gribben)

#### *Multiples Myelom*

Abstract [#8006](#): First clinical (phase 1b/2a) study of iberdomide (CC-220; IBER), a CELMoD, in combination with dexamethasone (DEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM). (Oral presentation; Sunday, June 2, 11:45 a.m. to 11:57 a.m., E451, lead author: Lonial)

#### *Myelofibrose*

Abstract [#7057](#): Fedratinib (FEDR) in myelofibrosis (MF) patients previously treated with ruxolitinib (RUX): A reanalysis of the JAKARTA-2 study. (Poster; Monday, June 3, 8 a.m. to 11 a.m., Hall A, lead author: Harrison)

#### *Pankreaskarzinom*

Abstract #4000: APACT: phase III, multicenter, international, open-label, randomized trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) for surgically resected pancreatic adenocarcinoma. (Oral presentation; Sunday, June 2, 9:45 a.m. to 9:57 a.m., Arie Crown Theater, lead author: Tempero)

#### [Abstract-Suche](#)

Mehr zum ASCO: <http://asco-meeting.com/>

*Quelle: Celgene*